NATERA INC (NTRA)

Natera Announces Publication of over 100 Peer-Reviewed Papers on SignateraTM

Here Are Billionaire Stanley Druckenmiller's 5 Biggest Stock Holdings

NTRA May 2025 Options Begin Trading

Natera Reports Third Quarter 2024 Financial Results

Natera Announces Completion of Signatera™ Analysis from the CALGB (Alliance)/SWOG 80702 Randomized, Phase III Clinical Trial in Colorectal Cancer

Notable Monday Option Activity: NVAX, NTRA, ALB

Natera to Participate in Upcoming Investor Conferences

Exploring NASDAQ:NTRA's high growth characteristics.

NATERA INC (NASDAQ:NTRA) is a candidate for high growth investors. Here's why.

Natera to Report its Third Quarter 2024 Results on November 12, 2024

Natera to Present New Renasight Data at ASN Kidney Week 2024

Court Orders Permanent Injunction Against NeoGenomics' Accused RaDaR Assay, as Case Enters New Phase

Tempus AI Stock Clears Technical Benchmark, Hitting 80-Plus RS Rating

A Relative Strength Rating upgrade for Tempus AI shows improving technical performance.

Natera Announces Three New Signatera Publications; Includes Groundbreaking Overall Survival Data Published in Nature Medicine and also Released at ESMO

First of its Kind Colorectal Cancer Data from Prospective GALAXY Study Released at ESMO; Demonstrates Signatera's Ability to Predict Overall Survival

Natera to Present New Signatera™ Colorectal Cancer Data at ESMO Showing 10X Advantage in Overall Survival

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

The recent stock market dip provided some discounts.

Natera Larger Than S&P 500 Component Akamai Technologies

NTRA Stock Earnings: Natera Beats EPS, Beats Revenue for Q2 2024

NTRA stock results show that Natera beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.

Natera Reports Second Quarter 2024 Financial Results